Recent research shows that the expression levels of TPD52L2 were upregulated in prostate cancer tissues, andincreased TPD52L2 expression is associated with clinical progression and poor prognosis in patients with prostate cancer, suggesting that TPD52L2 may be a potential prognostic marker for patients with prostate cancer (Ren et al., 2017). This evidence concerns the gene TPD52L2 and Familial prostate cancer.